Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
In a recent transaction reported to the SEC, Moat Ross, the Chief Commercial Officer of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA), sold 18,259 shares of the company’s Class A Ordinary Shares. According to InvestingPro data, the company maintains a "GREAT" financial health score, with analysts setting price targets between $30-$40. The shares were sold on April 21, 2025, at a weighted average price of $20.29 per share, totaling approximately $370,475.
This sale was conducted under a prearranged 10b5-1 trading plan, which had been executed by Ross on May 3, 2024. Following this transaction, Ross holds 9,415 shares directly. The sales were executed through a broker-dealer in multiple trades, with prices ranging between $20.05 and $20.53 per share. The company shows strong fundamentals with a current ratio of 3.3, holding more cash than debt on its balance sheet - one of several key insights available through InvestingPro’s comprehensive research reports.
In other recent news, Kiniksa Pharmaceuticals has announced the initiation of a Phase 2/3 clinical trial for its heart drug KPL-387, expected to commence in mid-2025. This trial aims to evaluate the treatment of recurrent pericarditis, building on promising Phase 1 data that suggest the potential for monthly dosing. The company plans to leverage the success of its existing treatment, ARCALYST, which has generated over $800 million since its 2021 launch. In addition to the new trial, Kiniksa has introduced an incentive plan to motivate executives to achieve critical milestones in the development of KPL-387, including the submission of a biologics license application and FDA approval for commercial sale. The incentive plan, known as the Executive 387 LTIP, offers cash awards, performance share units, and stock options based on milestone achievements. Kiniksa has also decided to discontinue the development of abiprubart for Sjögren’s Disease while continuing to develop other promising treatments like KPL-1161. These developments reflect Kiniksa’s strategic focus on advancing its drug pipeline and addressing unmet medical needs in the cardiovascular space.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.